Beller 1985.

Methods	Design: Double‐blind randomized placebo controlled multiple phase crossover design (2 days x 4) Order of dose conditions randomized separately for each patient
Participants	Country: USA Number: 8 inpatients in a geropsychiatric unit. Sex: 4 males and 4 females Age: 58‐83 years Diagnosis Criteria: DSM III for PDD Severity of AD: moderate to moderately severe Reisberg scores 3‐5 MIT scores 6‐13
Interventions	1. placebo 2. oral physostigmine 0.5 mg every 2 hours 7 doses per day (3.5 mg per day) 3. oral physostigmine 1.0 mg every 2 hours 7 doses per day (7.0 mg/day) 4. oral physostigmine 2.0 mg every 2 hours 7 doses per day (14.0 mg/day)
Outcomes	BSRT SCAG BPRS NOSIE
Notes	Outcomes assessed on the second day of treatment.